---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-101"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-101. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 44 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-101"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-101

<a id="heading-3.1.6"></a>

## 3.1.6 ABX464-101

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov record

> “This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids followed by a one-month follow-up period.”
> “Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.1-2"></a>

#### Proof-of-concept purpose described by the sponsor

> “ABX464-101 is an ongoing Phase 2a proof-of-concept study aimed at evaluating the safety and efficacy of ABX464 50 mg given once daily versus placebo for two months in subjects with moderate-to-severe active ulcerative colitis who have failed or are intolerant to immunomodulators, anti-TNFα, vedolizumab and/or corticosteroids.”

Source: [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2017-11-16”
> “Primary Completion (Actual) 2018-07-25”
> “Study Completion (Actual) 2019-02-04”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.2-2"></a>

#### Results posting date

> “Results First Posted 2023-02-08”

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.2-3"></a>

#### Registered locations

> “This study has 19 locations”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.2-4"></a>

#### Centers and countries reported by the sponsor

> “This clinical study was conducted in 15 centers in six European countries: Belgium, France, Germany, Austria, Hungary and Poland.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

<a id="topic-3.1.6.2-5"></a>

#### Centers and countries at the time of the extension study authorization

> “This clinical study is being conducted in 18 centers in eight European countries. Full regulatory and ethics committee authorizations already have been obtained in Belgium, France, Hungary, Poland, Czech Republic, Spain and Germany.”

Source: [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients)

Additional sources: [Abivax ABX464-101 protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/Prot_000.pdf)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Interventional model description | “Double-blind, placebo-controlled, randomized study” |
| Masking description | “Double-Blind Treatment” |
| Primary purpose | “Treatment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “32” |

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.3-2"></a>

#### Randomization ratio and treatment period

> “Eligible subjects will be randomized according to a 2/1 ratio in two different groups of treatment. Randomized subjects who will receive 50 mg ABX464 orally once daily for 56 days.”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.3-3"></a>

#### Randomized, double-blind design and central endoscopy reading described by the sponsor

> “ABX464-101 was a randomized, double-blind, placebo-controlled Phase 2a study evaluating the safety and efficacy of ABX464 50mg given orally once-daily for two months in subjects with moderate-to-severe active ulcerative colitis who have failed on immunomodulators, anti-TNFα, vedolizumab and/or corticosteroids.”
> “Twenty-nine of the 32 recruited patients, randomized 2:1 to receive ABX464 as a once daily oral tablet or placebo, have completed the study per protocol, which employed state-of-the art technologies for monitoring potential treatment effects, including numerical recording of the colonoscopies with centralized reading.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

<a id="topic-3.1.6.3-4"></a>

#### Optional roll-over into the open-label extension

> “In four countries, patients who completed the ABX464-101 study had the option to roll over into study ABX464-102, a 12-month open-label follow-up study.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

<a id="topic-3.1.6.3-5"></a>

#### Induction phase of the phase 2 program

> “Obefazimod 50 mg (n=23)”
> “Placebo (n=9)”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

Additional sources: [Abivax ABX464-101 protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/Prot_000.pdf)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Disease activity and background therapy in the ClinicalTrials.gov record

> “Diagnosis of moderate to severe active UC confirmed by endoscopy and histology at least 12 weeks prior to screening visit. Moderate to severe active UC defined by Mayo Clinic Score (MCS) of 6 to 12 inclusive (on a scale of 0-12). Moderate to severe active UC should be confirmed at screening visit with a centrally read MCS endoscopy score of at least 2 (on a scale of 0-3);”
> “Subjects receiving oral corticosteroids must have been on a stable dose of prednisone or prednisone equivalent ≤20 mg/day) or on beclomethasone diproprionate (≤5mg/day) or on budesonide MMX (≤9mg/day), for ≥2 weeks before first dosing (i.e. baseline);”
> “Subjects who have previously received anti-tumor necrosis factor (TNF) therapy or vedolizumab must have discontinued therapy ≥8 weeks before first dosing (i.e. baseline);”
> “18 Years to 70 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Subject with Crohn's Disease (CD), indeterminate colitis (IC) or presence or history of fistula with CD;”
> “History of toxic megacolon, abdominal abscess, symptomatic colonic stricture or stoma; history or is at imminent risk of colectomy;”
> “History or current evidence of colonic dysplasia or adenomatous colonic polyps.”
> “Subject with significant and known active infections at screening such as Infected abscess, positive for Clostridium difficile (stool antigen and toxin), CMV, TB and recent infectious hospitalization;”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.4-3"></a>

#### Prior treatment failure described by the sponsor

> “This clinical trial was conducted in 32 patients for induction treatment of moderate-to-severe ulcerative colitis (UC), refractory to anti-TNF monoclonal antibodies or corticosteroids.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

Additional sources: [Abivax ABX464-101 protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/Prot_000.pdf)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Arms in the ClinicalTrials.gov record

> “Subjects will receive 50 mg of ABX464 orally once daily for 56 days.”
> “Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.”
> “Placebo matching with ABX464”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.5-2"></a>

#### Capsule dosage form in the posted adverse event groups

> “Participants received 1 oral capsule containing ABX464 daily for 56 days”
> “Participants received 1 oral capsule containing placebo daily for 56 days”

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.5-3"></a>

#### Permitted background therapy at stable doses

> “Subjects who are on oral 5-aminosalicylic acid must have been on a stable dose ≥4 weeks before first dosing (i.e. baseline);”
> “Subjects who are receiving immunosuppressants in the form of azathioprine, 6-mercaptopurine, or methotrexate needed to be on a stable dose for 4 weeks before first dosing (i.e. baseline).”
> “Topical corticosteroids and topical 5-aminosalicylic acid preparations must have been withdrawn ≥2 weeks before first dosing (i.e. baseline);”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

##### Registered primary outcome measure

> “Number of Subjects With Treatment-emergent Adverse Events”
> “Number of treatment-emergent adverse events in the ABX464 treated subjects compared to placebo”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.6.1-2"></a>

##### Clinical remission registered as the primary efficacy endpoint among secondary outcomes

> “Percentage of subjects receiving ABX464 with clinical remission according to the Total Mayo Score at Week 8 compared to placebo (primary efficacy endpoint)”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.6.1-3"></a>

##### Other registered secondary outcome measures

> “Percentage of patients with fecal calprotectin levels > 50µg/g at Week 8 compared to placebo”
> “Change from baseline in Total Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 12; 12 being the worst score) - 4-component Scale: Rectal bleeding, Stool frequency, Mucosal appearance and Physician Global Assessment”
> “Change from baseline in Partial Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 9, with 9 indicating the worst score. It is a three-component scale assessing rectal bleeding, stool frequency, and the physician's global assessment.”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

Additional sources: [Abivax ABX464-101 protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/Prot_000.pdf)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Planned sample size stated in the ABX464-102 protocol

> “Not applicable / Maximum 30 subjects (i.e. ABX464-101’s sample size)”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.6.7.1-2"></a>

##### Participants randomized

> “32 patients were randomized (23 ABX464 patients/9 placebo).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.6.7.1-3"></a>

##### Participants analyzed in the posted results

| Analysis | ABX464 | Placebo |
| --- | --- | --- |
| Baseline and safety analysis | “23” | “9” |
| Efficacy outcomes (total Mayo score, partial Mayo score, fecal calprotectin) | “20” | “9” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

Additional sources: [Abivax ABX464-101 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/SAP_001.pdf)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

##### Analysis populations in the posted results

> “The safety analysis set included all participants who received at least 1 dose of ABX464.”
> “All subjects who received at least 1 dose of study treatment”
> “Subjects in the FAS without any major protocol deviations and who completed the study (Day 56)”

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.7.2-2"></a>

##### Statistical tests in the posted results

| Outcome | Method |
| --- | --- |
| Treatment-emergent adverse events | “Chi-squared” |
| Clinical remission | “Chi-squared” |
| Fecal calprotectin | “ANCOVA” |
| Total Mayo score | “ANCOVA” |
| Partial Mayo score | “ANCOVA” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

Additional sources: [Abivax ABX464-101 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/SAP_001.pdf)

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

##### Participant flow in the posted results

| Milestone | ABX464 | Placebo |
| --- | --- | --- |
| Started | “23” | “9” |
| Completed | “21” | “9” |
| Not completed | “2” | “0” |
| Reason not completed: adverse event | “1” | “0” |
| Reason not completed: withdrawal by subject | “1” | “0” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.1-2"></a>

##### Participants completing per protocol, as reported by the sponsor

> “Twenty-nine of the 32 recruited patients, randomized 2:1 to receive ABX464 as a once daily oral tablet or placebo, have completed the study per protocol”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

<a id="topic-3.1.6.8.1-3"></a>

##### Roll-over into the ABX464-102 extension

> “At the end of the completed 2 months induction treatment study, 22 Patients (15 previously treated with ABX464 and 7 on placebo) were enrolled into the open-label maintenance study with ABX464 50mg daily (ABX464-102) regardless of what treatment they had previously received.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

##### Age, sex, and race in the posted results

| Characteristic | ABX464 (N=23) | Placebo (N=9) | Total (N=32) |
| --- | --- | --- | --- |
| Age between 18 and 65 years | “19” | “9” | “28” |
| Age 65 years or older | “4” | “0” | “4” |
| Female | “11” | “1” | “12” |
| Male | “12” | “8” | “20” |
| White | “23” | “9” | “32” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.2-2"></a>

##### Baseline disease activity, disease duration, and prior advanced therapy

No evidence found.

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Clinical remission, clinical response, and endoscopic outcomes at week 8 reported by the sponsor

> “At the end of the eight-week induction of the phase 2a proof-of-concept clinical study in ulcerative colitis, 35% and 70% of patients in the ABX464 active group achieved clinical remission and clinical response versus 11.1% and 33.3% in the placebo group, respectively. Endoscopic improvement and remission were observed in 50% and 10% of patients receiving ABX464, respectively, versus 11.1% each for placebo.”

Source: [Abivax press release, phase 2a Gastroenterology publication (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-publishes-data-abx464-induction-and-long-term-maintenance)

<a id="topic-3.1.6.8.3-2"></a>

##### Week 8 results stated in the ABX464-102 protocol

> “Clinical Remission rate of 35.0 % of ABX464 patients (Placebo = 11.1%)”
> “Mucosal Healing rate of 50.0 % (p=0.03) of ABX464 patients (Placebo = 11.1%)”
> “Clinical Response rate of 70.0 % of ABX464 patients (Placebo = 33.0%)”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.6.8.3-3"></a>

##### Statistical comparisons of week 8 outcomes reported by the sponsor

> “The proportion of subjects achieving clinical remission was greater in the ABX464 group than in the placebo group (35.0% vs. 11.1%, p=ns). The difference between ABX464 and placebo treated patients in colorectal mucosal healing was statistically significant (50% vs. 11%, p=0.034).”
> “Furthermore, the onset of the therapeutic effect of ABX464 was rapid, with a reduction of the pMS between ABX464 and placebo being observed at the first assessment following treatment for two weeks, which became significant at eight weeks (-3.9 vs. -1.8, p=0.029; likelihood ratio CHI-square test). Similarly, the difference of the reduction of the total Mayo Score (tMS) after eight weeks was statistically significant (-4.6 vs. -2.1, p=0.029).”

Source: [Abivax press release, phase 2a six-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-impressive-new-phase-2a-abx464-ulcerative)

<a id="topic-3.1.6.8.3-4"></a>

##### Topline statistical comparisons and fecal calprotectin reported in 2018

> “The difference between ABX464 and placebo in colorectal mucosal healing was statistically significant (p<0.03).”
> “Similarly, the difference of the reduction of the total Mayo score”
> “after eight weeks was statistically significant (p<0.03).”
> “Calprotectin, the best studied biomarker in ulceratice colitis, was markedly reduced (4.4-fold) in patients who received ABX464 in comparison to placebo (1.6-fold) after 4 weeks of treatment.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

<a id="topic-3.1.6.8.3-5"></a>

##### Clinical remission at week 8 in the posted results, with arm titles as the record lists them

| Field | First arm listed | Second arm listed |
| --- | --- | --- |
| Arm/group title | “ABX464 Matching Placebo Treatment Arm” | “ABX464 Treatment Arm” |
| Overall number of participants analyzed | “20” | “9” |
| Participants in clinical remission | “7” | “1” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.3-6"></a>

##### Mayo score change and fecal calprotectin at week 8 in the posted results

| Outcome | ABX464 (n=20) | Placebo (n=9) |
| --- | --- | --- |
| Change from baseline in total Mayo score, mean (SD) | “-4.6(2.8)” | “-2.1(2.5)” |
| Change from baseline in partial Mayo score, mean (SD) | “-3.9(2.2)” | “-1.8(2.0)” |
| Participants with fecal calprotectin above 50 µg/g | “15” | “8” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.3-7"></a>

##### miR-124 expression in blood during ABX464-101 and ABX464-102

> “The measurement of miR124 relative gene expression by qPCR using whole blood samples was included in both ABX464-101 and -102.”
> “A total of 19 patients were sampled on day 0, 28, 56 of ABX464-101 and on day 365 (while in ABX464-102). Statistically significant increases of miR124 expression were observed at all these time points.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.6.8.3-8"></a>

##### Review summary of the proof-of-concept study

> “In vivo, in a proof-of-concept clinical study, ABX464 showed robust and consistent efficacy in ulcerative colitis (UC).”

Source: [Tazi et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33387693/)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Participants with treatment-emergent adverse events (primary outcome)

| Measure | ABX464 | Placebo |
| --- | --- | --- |
| Overall number of participants analyzed | “23” | “9” |
| Participants with treatment-emergent adverse events | “18” | “5” |
| Time frame | “Week 8” | “Week 8” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.5-2"></a>

##### Deaths, serious adverse events, and other adverse events in the posted results

| Measure, affected / at risk (%) | ABX464 | Placebo |
| --- | --- | --- |
| All-cause mortality | “0/23 (0.00%)” | “0/9 (0.00%)” |
| Serious adverse events, total | “0/23 (0.00%)” | “1/9 (11.11%)” |
| Nephrolithiasis left side (serious) | “0/23 (0.00%)” | “1/9 (11.11%)” |
| Other (not including serious) adverse events, total | “18/23 (78.26%)” | “5/9 (55.56%)” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.5-3"></a>

##### Other adverse events in at least two participants of either group

| Event, affected / at risk (%) | ABX464 | Placebo |
| --- | --- | --- |
| Abdominal pain | “4/23 (17.39%)” | “1/9 (11.11%)” |
| Headache | “4/23 (17.39%)” | “0/9 (0.00%)” |
| Abdominal pain upper | “3/23 (13.04%)” | “0/9 (0.00%)” |
| Nausea | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Chest pain | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Influenza like illness | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Hypophosphataemia | “1/23 (4.35%)” | “2/9 (22.22%)” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.5-4"></a>

##### Adverse event collection period

> “From baseline up to 4 weeks post last dose of study drug (up to 63 Days)”

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.5-5"></a>

##### Sponsor statement on safety

> “As observed in the other studies with ABX464, the product candidate was considered to be safe and well tolerated in ABX464-101. No severe adverse events attributed to ABX464 were reported in the trial.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary

ABX464-101 was a randomized, double-blind, placebo-controlled phase 2a study in which 32 participants with moderately to severely active ulcerative colitis were randomized 2:1 to obefazimod 50 mg (23 participants) or placebo (9 participants) once daily for 8 weeks, at sites in six European countries. The registered primary endpoint was the number of participants with treatment-emergent adverse events; clinical remission by the total Mayo score at week 8 was registered as an outcome described as the “primary efficacy endpoint”. Efficacy was analyzed in participants without major protocol deviations who completed day 56 (20 receiving obefazimod and 9 receiving placebo), and the sponsor reported that 29 of the 32 participants “completed the study per protocol”. The planned sample size, stated in the ABX464-102 protocol, was a maximum of 30 participants, and no power calculation was located. Clinical remission at week 8 was reported as 35.0% with obefazimod and 11.1% with placebo, a difference the sponsor reported as not significant. The posted record lists the arm titles of the clinical remission outcome in the reverse order of the other outcomes, so its arm labels do not match its participant counts. The posted results analyze the change in partial and total Mayo scores by ANCOVA, whereas a 2019 press release reports p=0.029 for both, naming a likelihood ratio chi-square test for the partial Mayo score, and the 2018 topline release reports p<0.03 for the total Mayo score. Placebo clinical response is given as 33.0% in the ABX464-102 protocol and 33.3% in a 2021 press release. The sponsor describes the study drug as a tablet, and the posted record as a capsule. All 32 participants were White. Baseline disease activity, disease duration, and prior advanced therapy exposure were not reported in the readable sources, because the protocol and statistical analysis plan posted on ClinicalTrials.gov are image-only scans. No health-related quality of life results were located.

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259); [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results); [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf); [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464); [Abivax press release, phase 2a six-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-impressive-new-phase-2a-abx464-ulcerative); [Abivax press release, phase 2a Gastroenterology publication (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-publishes-data-abx464-induction-and-long-term-maintenance)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
